Építés alatt – nem éles oldal
Belépés
LeállítvaNo phase

Assay to Measure Beta Blocker Adherence

Megadott ok: Quest Diagnostics terminated study early - did not want to continue to support single-site study

Key facts

Where
Akron, Egyesült ÁllamokSee the site

Where in Egyesült Államok

  • Summa Health SystemAkron, Egyesült ÁllamokNo longer taking part

Trial details

Who runs it
Summa Health System
Trial code
NCT05251974
Record updated
2023. november 22.
Original description
This study will assess the feasibility and efficacy of using serum assay developed by Quest Diagnostics to detect the presence of beta blockers, specifically carvedilol and metoprolol succinate, in patients with heart failure.Read full original descriptionShow less

The Effect of Medication Compliance, Verified With Medication Level Testing, on Unplanned Hospital Readmission or Urgent Outpatient Visit in Patients With Acute Decompensated Heart Failure

This study will assess the feasibility and efficacy of using serum assay developed by Quest Diagnostics to detect the presence of beta blockers, specifically carvedilol and metoprolol succinate, in patients with heart failure.

Inclusion: Age 18-89; Admitted for primary diagnosis of heart failure with reduced ejection fraction; Prescribed carvedilol or metoprolol succinate for beta blocker therapy; Will be following up at 95 Arch St. Clinic.

Exclusion: Patients with prior heart transplant or a left ventricular assist device; Under age 18/over age 89; Patients that plan to follow up somewhere other than the 95 Arch St. Clinic; Patient is unable to provide consent.

ClinicalTrials.gov NCT05251974